Form 4 for BLFS BIOLIFE SOLUTIONS INC
Accepted 2022-03-09 00:00:00 ET · period of report 2022-02-24 · accession 0001437749-22-005775 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-09 | 2022-02-24 | BLFS | DE GREEF RODERICK | COO, Pres | A - Grant | — | +23.4K | 115.2K | +25% | — |
| D | 2022-03-09 | 2022-02-24 | BLFS | DE GREEF RODERICK | COO, Pres | A - Grant | $0.00 | +23.4K | 23.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-24 | A | A | 23,365 | — | 115,177 | D | — | — | (F1) The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests on January 3, 2023. |
| 2 | Derivative | Restricted Stock Award | 2022-02-24 | A | A | 23,365 | $0.00 | 23,365 | D | $0.00 · — to — | 23,365 Common Stock | (F2) The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. |